Key Points
- Oliver Engert bought a total of 4,000 Enovis shares across five trades in late Feb–early Mar (about $98,242 total); after the Mar 6 purchase he owned 45,640 shares (a 1.67% increase on that trade) valued at roughly $1.11M.
- Q4 EPS of $0.95 beat Street estimates ($0.81) while revenue of $575.8M missed expectations; Enovis has a negative net margin but issued FY2026 EPS guidance of 3.52–3.73, and analysts maintain a consensus “Moderate Buy” with an average target of $47.43.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert purchased 750 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $24.41 per share, with a total value of $18,307.50. Following the purchase, the insider owned 45,640 shares of the company's stock, valued at approximately $1,114,072.40. This trade represents a 1.67% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Oliver Engert also recently made the following trade(s):
- On Monday, March 9th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average price of $23.39 per share, with a total value of $23,390.00.
- On Wednesday, March 4th, Oliver Engert acquired 250 shares of Enovis stock. The stock was acquired at an average cost of $25.10 per share, with a total value of $6,275.00.
- On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average price of $24.77 per share, with a total value of $24,770.00.
- On Friday, February 27th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was acquired at an average price of $25.50 per share, with a total value of $25,500.00.
Enovis Stock Performance
Shares of ENOV stock opened at $23.87 on Wednesday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -1.15 and a beta of 1.46. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The firm's 50 day moving average is $23.97 and its 200 day moving average is $27.93. Enovis Corporation has a 12 month low of $21.00 and a 12 month high of $40.69.
Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. During the same period in the previous year, the business earned $0.98 EPS. Enovis's revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on ENOV shares. Zacks Research raised shares of Enovis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 4th. BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Canaccord Genuity Group lowered their price target on Enovis from $58.00 to $50.00 and set a "buy" rating on the stock in a report on Wednesday, December 17th. Evercore reissued an "outperform" rating on shares of Enovis in a report on Monday, January 12th. Finally, UBS Group restated a "buy" rating and issued a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $47.43.
Get Our Latest Research Report on Enovis
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in ENOV. Capital Fund Management S.A. bought a new stake in Enovis during the second quarter worth about $1,682,000. Assenagon Asset Management S.A. bought a new position in shares of Enovis during the 3rd quarter valued at about $4,045,000. Impax Asset Management Group plc increased its position in shares of Enovis by 47.5% during the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company's stock valued at $9,425,000 after purchasing an additional 100,000 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Enovis by 56.0% during the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company's stock valued at $4,382,000 after buying an additional 50,156 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Enovis by 32.4% in the 2nd quarter. Rhumbline Advisers now owns 172,341 shares of the company's stock worth $5,405,000 after buying an additional 42,138 shares during the last quarter. Institutional investors own 98.45% of the company's stock.
Enovis Company Profile
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
